Cefquinome Sulfate
产品说明书
 |
同义名 : | 硫酸头孢喹肟 ;Cefquinome (sulfate);HR 111V sulfate |
| CAS号 : | 118443-89-3 | |
| 货号 : | A306679 | |
| 分子式 : | C23H26N6O9S3 | |
| 纯度 : | 97% | |
| 分子量 : | 626.68 | |
| MDL号 : | MFCD11864966 | |
| 存储条件： |
Pure form Keep in dark place,Inert atmosphere,2-8°C In solvent -20°C:3-6个月-80°C:12个月 |
|
| 溶解度 : |
DMSO: 120 mg/mL(191.48 mM)，配合低频超声助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO H2O: 2 mg/mL(3.19 mM)，配合低频超声助溶 |
|
| 动物实验配方： |
| 生物活性 | |||
|---|---|---|---|
| 描述 | Cefquinome Sulfate (CS) is a fourth-generation cephalosporin, which has been developed solely for veterinary use[3]. Cefquinome inhibited members of the Enterobacteriaceae at less than or equal to 0.5 microgram/ml for Escherichia coli, Klebsiella pneumoniae, K. oxytoca, Citrobacter diversus, Salmonella Shigella, Proteus mirabilis, Morganella, and Providencia. Overall, the in vitro activity of cefquinome was comparable with aminothiazolyl cephalosporins. It inhibited some Enterobacter and Citrobacter freundii resistant to ceftazidime as did cefpirome and cefepime[4]. Cefquinome (88.8mg cefquinome sulphate per 8mL) was administered by the intramammary route to all quarters and/or "systemically" via the perfusion fluid at concentrations similar to those measured in plasma following intramuscular administration of 1mg cefquinome per kg body weight. For the treatment of acute mastitis a combination of both intramammary and systemic administration is likely to be advantageous in order to rapidly produce maximum cefquinome concentrations in all regions of the udder[5]. Lower doses of cefquinome can be administered as aerosols providing high local drug concentrations in lung, but additional optimization of formulation is needed to improve distribution and persistence in lung[6]. | ||
| 实验方案 | |||
|---|---|---|---|
| 1mg | 5mg | 10mg | |
|
1 mM 5 mM 10 mM |
1.60mL 0.32mL 0.16mL |
7.98mL 1.60mL 0.80mL |
15.96mL 3.19mL 1.60mL |
| 参考文献 |
|---|